PTN - Palatin stock jumps 16% on positive Phase 3 data for eye drug
2024-04-08 09:49:02 ET
More on Palatin Tech
- Palatin Technologies, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript
- Palatin stock plunges 40% on mixed Phase 3 data for dry eye drug
- Palatin Tech GAAP EPS of -$0.56 misses by $0.23, revenue of $2.03M beats by $0.27M
- Seeking Alpha’s Quant Rating on Palatin Tech